Since February 2008 Karo Bio and Zydus Cadila, one of India's leading healthcare companies, has initiated a three year strategic drug discovery and development collaboration. The companies will collaborate to discover and develop novel, selective glucocorticoid receptor (GR) modulators for treatment of inflammatory diseases. Karo Bio will leverage its expertise in nuclear receptor drug discovery including structural biology, drug design and compound characterisation. Zydus Cadila will leverage its expetise in carrying out a focused drug discovery and development programme, starting from pre-clinical candidate selection, undertaking pre-clinical studies, filing of the Investigational New Drug Application and human clinical trials. Both parties will equally share risk and rewards in the collaboration programme.